Random Structure - EMD-7860
Random EMDB
Recent Publications
Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer.
Kumar R, Deshpande S, Sewall LM, Ozorowski G, Cottrell CA, Lee WH, Holden LG, Richey ST, Chandrawacar AS, Dhiman K, Ashish F, Kumar V, Ahmed S, Hingankar N, Kumar N, Murugavel KG, Srikrishnan AK, Sok D, Ward AB, Bhattacharya J.
PLoS Pathog., April 7, 2021, PMID:33826683
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike.
Derking R, Allen JD, Cottrell CA, Sliepen K, Seabright GE, Lee WH, Aldon Y, Rantalainen K, Antanasijevic A, Copps J, Yasmeen A, Cupo A, Cruz Portillo VM, Poniman M, Bol N, van der Woude P, de Taeye SW, van den Kerkhof TLGM, Klasse PJ, Ozorowski G, van Gils MJ, Moore JP, Ward AB, Crispin M, Sanders RW.
Cell Rep., April 6, 2021, PMID:33826885
A cross-neutralizing antibody between HIV-1 and influenza virus.
Lee CD, Watanabe Y, Wu NC, Han J, Kumar S, Pholcharee T, Seabright GE, Allen JD, Lin CW, Yang JR, Liu MT, Wu CY, Ward AB, Crispin M, Wilson IA.
PLoS Pathog., March 22, 2021, PMID:33750987
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes.
Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, Liu STH, Simon V, Krammer F, Ward AB, Palese P, Wilson PC, Nachbagauer R.
Proc Natl Acad Sci U S A., Feb. 23, 2021, PMID:33593910
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
Andreano E, Nicastri E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, Vacca F, Cardamone D, De Santi C, Torres JL, Ozorowski G, Benincasa L, Jang H, Di Genova C, Depau L, Brunetti J, Agrati C, Capobianchi MR, Castilletti C, Emiliozzi A, Fabbiani M, Montagnani F, Bracci L, Sautto G, Ross TM, Montomoli E, Temperton N, Ward AB, Sala C, Ippolito G, Rappuoli R.
Cell, Feb. 23, 2021, PMID:33667349
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL, LaBranche C, Montefiori DC, Ringe RP, van Gils MJ, Moore JP, Klasse PJ, Crispin M, King NP, Ward AB, Sanders RW.
NPJ Vaccines, Feb. 9, 2021, PMID:33563983
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
Charles TP, Burton SL, Arunachalam PS, Cottrell CA, Sewall LM, Bollimpelli VS, Gangadhara S, Dey AK, Ward AB, Shaw GM, Hunter E, Amara RR, Pulendran B, van Gils MJ, Derdeyn CA.
PLoS Pathog, Feb. 8, 2021, PMID:33556148
Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins.
Bouwman KM, Tomris I, Turner HL, van der Woude R, Shamorkina TM, Bosman GP, Rockx B, Herfst S, Snijder J, Haagmans BL, Ward AB, Boons GJ, de Vries RP.
PLoS Pathog., Feb. 8, 2021, PMID:33556147
Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization.
Wang Y, Howell KA, Brannan J, Agans KN, Turner HL, Wirchnianski AS, Kailasan S, Fusco M, Galkin A, Chiang CI, Zhao X, Saphire EO, Chandran K, Ward AB, Dye JM, Aman MJ, Geisbert TW, Li Y.
J Virol, Feb. 3, 2021, PMID:33536172
Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination.
Han J, Schmitz AJ, Richey ST, Dai YN, Turner HL, Mohammed BM, Fremont DH, Ellebedy AH, Ward AB.
Cell Rep, Jan. 26, 2021, PMID:33503432